{"id":68245,"date":"2026-06-15T22:29:53","date_gmt":"2026-06-15T14:29:53","guid":{"rendered":"https:\/\/flcube.com\/?p=68245"},"modified":"2026-06-15T22:29:54","modified_gmt":"2026-06-15T14:29:54","slug":"gritpharma-secures-nmpa-approval-for-doxylamine-as-chinas-first-novel-short-term-insomnia-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68245","title":{"rendered":"Gritpharma Secures NMPA Approval for Doxylamine as China&#8217;s First Novel Short-Term Insomnia Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Gritpharma Co., Ltd.<\/strong> announced it has received <strong>marketing approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for <strong>doxylamine<\/strong> as a treatment for <strong>short-term insomnia<\/strong>, establishing the drug as the <strong>first and only novel therapy specifically approved<\/strong> for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Doxylamine<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Short-term insomnia (sleep disturbance symptoms lasting \u2264 3 months)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Non-psychotropic substance<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First novel drug specifically approved for short-term insomnia in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-differentiation-amp-safety-profile\" class=\"wp-block-heading\">Clinical Differentiation &amp; Safety Profile<\/h2>\n\n\n\n<h3 id=\"h-mechanism-of-action\" class=\"wp-block-heading\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> H1 histamine receptors in the central nervous system<\/li>\n\n\n\n<li><strong>Pathway:<\/strong> Crosses blood-brain barrier to produce sedative effect<\/li>\n\n\n\n<li><strong>Key Distinction:<\/strong> No direct agonistic action on GABA-A receptors (unlike benzodiazepines)<\/li>\n\n\n\n<li><strong>Addiction Risk:<\/strong> None \u2013 carries no risk of physical or psychological dependence<\/li>\n\n\n\n<li><strong>Discontinuation Effects:<\/strong> No rebound insomnia or withdrawal symptoms<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-safety-advantages-vs-traditional-therapies\" class=\"wp-block-heading\">Safety Advantages vs. Traditional Therapies<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Doxylamine<\/th><th>Traditional Benzodiazepines\/Non-Benzodiazepines<\/th><\/tr><\/thead><tbody><tr><td><strong>Addiction Potential<\/strong><\/td><td>None<\/td><td>Significant risk<\/td><\/tr><tr><td><strong>Dependence<\/strong><\/td><td>No physical or psychological dependence<\/td><td>Common with prolonged use<\/td><\/tr><tr><td><strong>Rebound Effects<\/strong><\/td><td>None upon discontinuation<\/td><td>Frequent rebound insomnia<\/td><\/tr><tr><td><strong>Regulatory Classification<\/strong><\/td><td>Non-psychotropic (general availability)<\/td><td>Category II psychotropic substances<\/td><\/tr><tr><td><strong>Prescription Requirements<\/strong><\/td><td>Available through general channels<\/td><td>Strict prescription limits<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-context-amp-unmet-need\" class=\"wp-block-heading\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<h3 id=\"h-insomnia-classification-icsd-3\" class=\"wp-block-heading\">Insomnia Classification (ICSD-3)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Short-term Insomnia:<\/strong> Sleep disturbance lasting \u2264 3 months<\/li>\n\n\n\n<li><strong>Chronic Insomnia:<\/strong> Persistent sleep difficulties > 3 months<\/li>\n\n\n\n<li><strong>Current Market Gap:<\/strong> Most existing therapies target chronic insomnia, leaving short-term cases underserved<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-market-opportunity\" class=\"wp-block-heading\">China Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Millions of Chinese adults experiencing short-term insomnia annually<\/li>\n\n\n\n<li><strong>Treatment Barriers:<\/strong> Strict controls on psychotropic sleep medications limit access<\/li>\n\n\n\n<li><strong>Healthcare Burden:<\/strong> Insomnia contributes to reduced productivity and increased healthcare utilization<\/li>\n\n\n\n<li><strong>Consumer Preference:<\/strong> Growing demand for safe, non-addictive sleep solutions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-accessibility\" class=\"wp-block-heading\">Commercial Accessibility<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Distribution Channels:<\/strong> General pharmacies, hospitals, and online platforms<\/li>\n\n\n\n<li><strong>Prescription Status:<\/strong> Non-prescription availability due to non-psychotropic classification<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Immediate nationwide availability without special regulatory restrictions<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Competitive positioning against both prescription and OTC sleep aids<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-precedent-amp-validation\" class=\"wp-block-heading\">Global Precedent &amp; Validation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Approval History:<\/strong> Previously approved for use in pregnant women, elderly, and children<\/li>\n\n\n\n<li><strong>Safety Record:<\/strong> Established safety profile across vulnerable populations<\/li>\n\n\n\n<li><strong>Regulatory Acceptance:<\/strong> Long-standing approval in multiple international markets<\/li>\n\n\n\n<li><strong>Clinical Evidence:<\/strong> Well-documented efficacy and safety in short-term insomnia management<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitive Factor<\/th><th>Gritpharma&#8217;s Position<\/th><\/tr><\/thead><tbody><tr><td><strong>First-Mover Advantage<\/strong><\/td><td>Only novel drug specifically approved for short-term insomnia<\/td><\/tr><tr><td><strong>Regulatory Classification<\/strong><\/td><td>Non-psychotropic status enables broader distribution<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Superior to controlled substances with addiction risks<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Unrestricted availability vs. prescription-only competitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This approval represents a <strong>transformative opportunity<\/strong> for Gritpharma to capture significant market share in China&#8217;s insomnia treatment segment. By addressing the underserved short-term insomnia population with a <strong>non-addictive, readily accessible therapy<\/strong>, the company positions itself to disrupt the traditional sleep aid market dominated by controlled substances.<\/p>\n\n\n\n<h2 id=\"h-implementation-amp-commercial-strategy\" class=\"wp-block-heading\">Implementation &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Launch:<\/strong> Immediate commercial availability through established pharmaceutical distribution networks<\/li>\n\n\n\n<li><strong>Physician Education:<\/strong> Educational campaigns highlighting safety advantages over traditional therapies<\/li>\n\n\n\n<li><strong>Consumer Awareness:<\/strong> Direct-to-consumer messaging emphasizing non-addictive benefits<\/li>\n\n\n\n<li><strong>Channel Development:<\/strong> Partnerships with pharmacy chains and e-commerce health platforms<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-future-development-opportunities\" class=\"wp-block-heading\">Future Development Opportunities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Additional Indications:<\/strong> Potential expansion to other sleep-related conditions<\/li>\n\n\n\n<li><strong>Combination Therapies:<\/strong> Exploration with complementary non-pharmacological approaches<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Leveraging China approval as foundation for other Asian markets<\/li>\n\n\n\n<li><strong>Product Line Extension:<\/strong> Development of optimized formulations or delivery systems<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market opportunities, commercial expectations, and regulatory implications. Actual results may differ due to risks including competitive dynamics, market adoption rates, and regulatory changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4799,15],"class_list":["post-68245","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-gritpharma","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gritpharma Secures NMPA Approval for Doxylamine as China&#039;s First Novel Short-Term Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for doxylamine as a treatment for short-term insomnia, establishing the drug as the first and only novel therapy specifically approved for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68245\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gritpharma Secures NMPA Approval for Doxylamine as China&#039;s First Novel Short-Term Insomnia Treatment\" \/>\n<meta property=\"og:description\" content=\"Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for doxylamine as a treatment for short-term insomnia, establishing the drug as the first and only novel therapy specifically approved for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68245\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T14:29:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T14:29:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68245#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68245\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gritpharma Secures NMPA Approval for Doxylamine as China&#8217;s First Novel Short-Term Insomnia Treatment\",\"datePublished\":\"2026-06-15T14:29:53+00:00\",\"dateModified\":\"2026-06-15T14:29:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68245\"},\"wordCount\":583,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Gritpharma\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68245#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68245\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68245\",\"name\":\"Gritpharma Secures NMPA Approval for Doxylamine as China's First Novel Short-Term Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-15T14:29:53+00:00\",\"dateModified\":\"2026-06-15T14:29:54+00:00\",\"description\":\"Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China's National Medical Products Administration (NMPA) for doxylamine as a treatment for short-term insomnia, establishing the drug as the first and only novel therapy specifically approved for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68245#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68245\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68245#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gritpharma Secures NMPA Approval for Doxylamine as China&#8217;s First Novel Short-Term Insomnia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gritpharma Secures NMPA Approval for Doxylamine as China's First Novel Short-Term Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China's National Medical Products Administration (NMPA) for doxylamine as a treatment for short-term insomnia, establishing the drug as the first and only novel therapy specifically approved for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68245","og_locale":"en_US","og_type":"article","og_title":"Gritpharma Secures NMPA Approval for Doxylamine as China's First Novel Short-Term Insomnia Treatment","og_description":"Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China's National Medical Products Administration (NMPA) for doxylamine as a treatment for short-term insomnia, establishing the drug as the first and only novel therapy specifically approved for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.","og_url":"https:\/\/flcube.com\/?p=68245","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T14:29:53+00:00","article_modified_time":"2026-06-15T14:29:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68245#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68245"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gritpharma Secures NMPA Approval for Doxylamine as China&#8217;s First Novel Short-Term Insomnia Treatment","datePublished":"2026-06-15T14:29:53+00:00","dateModified":"2026-06-15T14:29:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68245"},"wordCount":583,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Gritpharma","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68245#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68245","url":"https:\/\/flcube.com\/?p=68245","name":"Gritpharma Secures NMPA Approval for Doxylamine as China's First Novel Short-Term Insomnia Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-15T14:29:53+00:00","dateModified":"2026-06-15T14:29:54+00:00","description":"Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China's National Medical Products Administration (NMPA) for doxylamine as a treatment for short-term insomnia, establishing the drug as the first and only novel therapy specifically approved for this indication in China. The approval addresses a significant gap in the insomnia treatment landscape, offering a non-addictive alternative to traditional benzodiazepine-based sleep aids.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68245#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68245"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68245#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gritpharma Secures NMPA Approval for Doxylamine as China&#8217;s First Novel Short-Term Insomnia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68245"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68245\/revisions"}],"predecessor-version":[{"id":68246,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68245\/revisions\/68246"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}